Manorama Industries Limited (MANORAMA.NS) Bundle
Manorama Industries' recent numbers demand attention: Q1 FY26 revenue jumped a staggering 117% YoY to ₹2,896 million, capping a FY25 topline of ₹7,710 million driven by exports that accounted for 73% of sales, while operating performance shows dramatic improvement with EBITDA surging to 27.3% margin (Q1 FY26) and PAT nearly doubling to ₹1,120 million in FY25 - juxtaposed against a net debt of ₹3,800 million as of September 2025 and a market P/E of 74.97; dive into the revenue mix, margin expansion, deleveraging moves, liquidity shifts (cash at ₹181 million and working capital cut from 151 to 97 days), valuation trade-offs, and listed risks to understand whether growth, profitability and capital efficiency like ROCE at 19.81% position the stock for the next leg of value creation
Manorama Industries Limited (MANORAMA.NS) - Revenue Analysis
- Q1 FY26 revenue: ₹2,896 million - 117% YoY growth driven by enhanced product mix and higher utilization of new fractionation capacity.
- FY25 full-year revenue: ₹7,710 million - 68.6% YoY growth supported by increased capacity, robust exports (73% of revenue), and higher contribution from value-added products.
- Revenue trajectory cited: ₹450 million in FY21 to ₹771 million in FY25 - a 71% increase over four years (product-line/segment perspective).
- Highest quarterly revenue: Q3 FY25 at ₹2,092 million - 112.5% YoY increase due to rising demand for specialty fats and successful commercialization of new fractionation capacity.
- Export contribution FY25: 73% of total revenue, underscoring a strong global presence.
- Growth enablers: diversified product portfolio, specialty fats for chocolate/confectionery, cosmetics applications, and innovation in fractionation.
| Metric | Value | Notes |
|---|---|---|
| Q1 FY26 Revenue | ₹2,896 million | 117% YoY growth |
| Q3 FY25 Quarterly Revenue | ₹2,092 million | Highest-ever quarter; 112.5% YoY growth |
| FY25 Full-Year Revenue | ₹7,710 million | 68.6% YoY growth; 73% exports |
| FY21 Revenue (reference) | ₹450 million | Baseline for multi-year trajectory |
| FY25 Revenue (segment/product-line figure) | ₹771 million | Referenced 4-year trajectory showing 71% increase vs FY21 |
| Export mix FY25 | 73% | Significant global sales exposure |
- Key demand drivers: specialty fats for chocolate & confectionery, creams & formulations for cosmetics, rising acceptance of value‑added product lines.
- Operational levers: new fractionation capacity commercialization, higher utilization rates, product-mix shift toward higher-margin SKUs, and export market penetration.
Manorama Industries Limited (MANORAMA.NS) - Profitability Metrics
Manorama Industries Limited has demonstrated marked improvement in operating profitability and margin expansion over recent reporting periods, driven by cost controls and operating leverage. Key reported metrics show strong EBITDA growth quarters and fiscal-year gains, alongside a substantial rise in PAT and expanding margins.- Q1 FY26: EBITDA surged 195% YoY to ₹790 million; EBITDA margin expanded 721 bps to 27.3%.
- FY25: Full-year EBITDA grew 160% YoY to ₹1,910 million; EBITDA margin reached 24.8%.
- Q3 FY25: EBITDA rose 253.4% YoY to ₹552 million; EBITDA margin expanded 1,051 bps to 26.4%.
- Q3 FY25 PAT margin expanded 656 bps to 14.1%.
- FY25 PAT nearly doubled to ₹1,120 million.
- Three-year average ROE: ~7%.
| Period | EBITDA (₹ million) | EBITDA YoY (%) | EBITDA Margin | PAT (₹ million) | PAT Margin | ROE (3-yr avg) |
|---|---|---|---|---|---|---|
| Q1 FY26 | 790 | +195% | 27.3% | - | - | ~7% |
| FY25 (Full Year) | 1,910 | +160% | 24.8% | 1,120 | (PAT nearly doubled YoY) | |
| Q3 FY25 | 552 | +253.4% | 26.4% | - | 14.1% (PAT margin) | |
| FY25 vs Prior | - | - | - | 1,120 | - |
Investors evaluating Manorama Industries Limited should consider the pace of margin expansion and operating leverage evidenced above, while monitoring sustainability of these gains and the moderate three-year ROE. Further investor-focused context is available here: Exploring Manorama Industries Limited Investor Profile: Who's Buying and Why?
Manorama Industries Limited (MANORAMA.NS) - Debt vs. Equity Structure
Between March and September 2025 Manorama Industries Limited executed visible balance-sheet shifts that impacted leverage, capital structure and return metrics. Key headline movements include reductions in gross borrowings, a notable rise in shareholders' equity and simultanous changes in net debt that require scrutiny for investment decisions.- Gross borrowings decreased from ₹4,808 million (Mar 2025) to ₹3,749 million (Sep 2025), a reduction of ₹1,059 million.
- Equity rose from ₹4,619 million (Mar 2025) to ₹5,709 million (Sep 2025), an increase of ₹1,090 million.
- Net debt increased to ₹3,800 million as of Sep 2025 from ₹2,500 million in FY24, reflecting higher leverage on a net basis despite lower gross borrowings.
- Debt-to-equity ratio improved following the combined effect of lower borrowings and higher equity, consistent with a deleveraging strategy.
- Capital efficiency metrics strengthened: ROE reached 28.05% and ROCE rose to 19.81% in FY25.
| Metric | Mar 2025 | Sep 2025 | FY24 (for comparison) |
|---|---|---|---|
| Gross Borrowings (₹ million) | 4,808 | 3,749 | - |
| Shareholders' Equity (₹ million) | 4,619 | 5,709 | - |
| Net Debt (₹ million) | - | 3,800 | 2,500 |
| Debt-to-Equity Ratio | 1.04 (approx.) | 0.66 (approx.) | - |
| ROE | - | 28.05% | - |
| ROCE | - | 19.81% | - |
- Interpretation pointers for investors:
- Reduction in gross borrowings improves solvency headroom and interest coverage potential.
- Equity growth strengthens the capital base, lowering financial risk and supporting future funding flexibility.
- Rising net debt versus FY24 signals operating or investing cash outflows that exceeded deleveraging-monitor working capital and capex trends.
- Robust ROE and ROCE indicate efficient use of capital despite mixed debt signals; track sustainability of these returns.
Manorama Industries Limited (MANORAMA.NS) - Liquidity and Solvency
Manorama Industries shows a mixed but improving liquidity and solvency profile through FY25 and the first half of FY26 (September 2025). Key movements point to better short-term liquidity, operational efficiency gains, and targeted deleveraging despite a rise in net debt year-on-year.- Cash & cash equivalents: ₹181 million as of September 2025, up from prior periods, signaling improved immediate liquidity.
- Working capital efficiency: Working capital days improved from 151 days to 97 days, reflecting faster receivables/stock turnover or extended payables management.
- Net debt: ₹3,800 million as of September 2025, higher than ₹2,500 million reported in FY24, indicating an increase in absolute leverage compared to FY24.
- Borrowings trend: Gross borrowings reduced from ₹4,808 million (March 2025) to ₹3,749 million (September 2025), evidencing active repayment and deleveraging steps during FY25-H1 FY26.
- Debt-to-equity: Improved on account of falling borrowings and a rise in equity, showing a strategic shift toward strengthening the capital structure.
- Capital efficiency: Return on Equity (ROE) reached 28.05% and Return on Capital Employed (ROCE) rose to 19.81% in FY25, indicating strong returns on shareholder and total capital.
| Metric | FY24 | FY25 | Sept 2025 / H1 FY26 |
|---|---|---|---|
| Cash & Cash Equivalents | - | - | ₹181 million |
| Working Capital Days | 151 days | - | 97 days |
| Net Debt | ₹2,500 million | - | ₹3,800 million |
| Gross Borrowings | - | ₹4,808 million (Mar 2025) | ₹3,749 million (Sep 2025) |
| Debt-to-Equity Ratio | Higher (FY24) | Improved (FY25) | Improved (Sep 2025) |
| ROE | - | 28.05% (FY25) | - |
| ROCE | - | 19.81% (FY25) | - |
- Implication: Improved cash buffers and shorter working capital cycles reduce liquidity risk, while reduced gross borrowings improve solvency ratios despite a higher reported net debt versus FY24-suggesting timing or non-cash factors affecting net-debt movements.
- Investor focus areas: monitor continued reduction in gross borrowings, trajectory of net debt, and sustainability of ROE/ROCE levels.
Manorama Industries Limited (MANORAMA.NS) - Valuation Analysis
Key valuation and capital-efficiency metrics for Manorama Industries show a mix of high market valuation, improving capital returns in FY25, and shifting leverage across the latest reporting periods.
- Price-to-Earnings (P/E): 74.97 - indicates a high valuation relative to current earnings.
- Three-year average Return on Equity (ROE): ~7% - moderate multi-year profitability versus equity.
- FY25 ROE: 28.05% - material improvement in capital returns in FY25.
- FY25 ROCE: 19.81% - stronger operating-capital efficiency in FY25.
- Borrowings: decreased from ₹4,808 million (March 2025) to ₹3,749 million (September 2025), reducing gross borrowings.
- Net debt: ₹3,800 million as of September 2025, up from ₹2,500 million in FY24 - net leverage increased despite lower gross borrowings.
| Metric | FY24 | March 2025 | September 2025 / FY25 |
|---|---|---|---|
| P/E ratio | - | - | 74.97 |
| 3‑yr average ROE | ~7% | - | ~7% |
| ROE (FY25) | - | - | 28.05% |
| ROCE (FY25) | - | - | 19.81% |
| Gross borrowings | ₹4,808 million (Mar 2025) | - | ₹3,749 million (Sep 2025) |
| Net debt | ₹2,500 million (FY24) | - | ₹3,800 million (Sep 2025) |
| Debt-to-equity (direction) | Higher (FY24) | Improved (Mar→Sep 2025) | Improved vs Mar 2025 |
- Implications for investors: high P/E signals elevated market expectations; FY25 ROE/ROCE gains point to improved capital efficiency that may justify premium if earnings sustain.
- Leverage note: gross borrowings declined between March and September 2025, aiding the debt-to-equity profile, but net debt rose year-on-year to ₹3,800 million, increasing financial leverage.
- Monitor earnings trajectory and cash generation to see if high valuation (P/E 74.97) is supported by recurring profitability and sustained ROCE/ROE levels.
Further context on shareholder activity and investor composition is available here: Exploring Manorama Industries Limited Investor Profile: Who's Buying and Why?
Manorama Industries Limited (MANORAMA.NS) - Risk Factors
Manorama Industries operates in tea, coffee, instant beverages and packaged foods; the company's margins and cash flows are exposed to multiple operational, market and macro risks. Below are the principal risk factors, quantified where possible and linked to practical impacts and mitigation levers.- Commodity price volatility
| Commodity | Recent market move (example) | Estimated margin impact |
|---|---|---|
| Tea (CTC & Orthodox) | Price swings of ±15-30% year-on-year seen historically | EBITDA change of ~-200 to +150 bps per 10% move |
| Coffee (robusta/arabica) | Global prices can vary ±20-40% over cycles | EBITDA change of ~-150 to +200 bps per 10% move |
| Packaging (film, board) | Input cost inflation of 10-25% noted in past cycles | Direct cost increase of ₹5-25 per kg equivalent products |
- Regulatory and environmental risks
- Currency risk
- Competitive pressures in FMCG & packaged foods
- Joint venture losses: Starbucks India exposure
- Input cost inflation and demand dynamics
| Risk | Typical near-term magnitude (illustrative) | Potential P&L/Balance sheet effect | Mitigation levers |
|---|---|---|---|
| Tea price spike | ±15-30% YoY | EBITDA swing -200 to +150 bps | Forward buying, seller contracts, product mix shift |
| Coffee price volatility | ±20-40% cyclic | EBITDA swing -150 to +200 bps | Hedging, blends, sourcing diversification |
| Packaging inflation | 10-25% | COGS rise; gross margin compression | Packaging redesign, supplier renegotiation |
| FX volatility | INR moves 5-15% annually | Net FX loss/gain = 0.5-2% of revenue | Natural hedges, forward contracts |
| JV losses (e.g., specialty retail) | Accumulated losses of ₹50-1,000M | Consolidated PAT drag until JV breakeven | Capital allocation review, minority stake management |
| Regulatory compliance | Capex/remediation ₹10-150M | One-off cash outflows; higher depreciation | Proactive compliance audits, phased capex |
Manorama Industries Limited (MANORAMA.NS) - Growth Opportunities
Manorama Industries Limited is targeting aggressive top-line expansion and geographic diversification as core drivers to reach a ₹1,000 crore revenue milestone by FY30. Key strategic levers include FMCG expansion, pharmaceutical butter development, value-added cosmeceuticals, new subsidiaries abroad, and improved sourcing and operational efficiencies.- Revenue target: ₹1,000 crore by FY30, up from guidance of ₹750 crore for FY25 (guidance expected to be surpassed in FY25).
- Near-term revenue momentum: on track to exceed ₹750 crore guidance for FY25 through stronger raw material sourcing and new customer additions.
- Product expansion: ramp-up in FMCG SKUs, launch and scale-up of pharmaceutical butter, and premium cosmeceutical formulations to capture higher-margin segments.
- Geographic expansion: six new subsidiaries incorporated (five in Africa, one in the UAE) plus planned entry to South America in coming quarters.
- Capital projects under evaluation: proposed Seed Storage Unit to secure raw-material continuity and reduce commodity volatility exposure.
- Sustainability & sourcing: emphasis on ethical sourcing, sustainable practices, and traceability to meet evolving retailer and regulatory demands.
| Metric/Initiative | Target / Status | Timeline | Expected Impact |
|---|---|---|---|
| Revenue Target | ₹1,000 crore | By FY30 | ~33%+ CAGR from FY25 midpoint (if FY25 ≈ ₹750 crore) |
| FY25 Guidance | ₹750 crore (to be surpassed) | FY25 | Near-term growth validation |
| Subsidiaries Incorporated | 6 (5 Africa, 1 UAE) | Recent | Market access, local sourcing, trade facilitation |
| South America Entry | Planned | Coming quarters | New demand pool; diversify revenue mix |
| Seed Storage Unit | Under evaluation | Planned (near-term capex) | Raw-material security; margin stability |
| Product Focus | FMCG, pharmaceutical butter, cosmeceuticals | Rollout & scale through FY26-FY30 | Higher-margin product mix |
| Sustainability Initiatives | Ethical sourcing, sustainable packaging, traceability pilots | Ongoing | Customer/retailer alignment; premium positioning |
- Operational efficiencies: focus on scale-driven procurement, route-to-market optimization, and manufacturing yield improvements to protect margins while growing volumes.
- Customer diversification: addition of new customers across geographies reduces single-market concentration risk and supports pricing power.
- Financial implications: achieving ₹1,000 crore by FY30 implies meaningful incremental EBITDA and free-cash-flow generation if current margin trajectory and operational controls are maintained.
Manorama Industries Limited (MANORAMA.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.